Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “combination”

418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 418
Index total 30,257
Page 7 / 18

Quick answer

This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

418 results for “combination” · 30,257 patents in full index Clear search

  1. US 11135225

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted

  2. US 11129823

    Combination treatment of ocular inflammatory disorders and diseases

    Aldeyra Therapeutics, Inc. · Granted Sep 28, 2021 · Expires Sep 23, 2041

    granted

  3. US 11116838

    Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

    Inovio Pharmaceuticals, Inc. · Granted Sep 14, 2021 · Expires Sep 9, 2041

    granted

  4. US 11110099

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted

  5. US 11110108

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted

  6. US 11110086

    Compounds useful as inhibitors of ATR kinase and combination therapies thereof

    Vertex Pharmaceuticals Incorporated · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted

  7. US 11103504

    Combination of a DNA condensation-inducing compound and an Eis inhibitor for antibiotic treatment

    ACADEMISCH MEDISCH CENTRUM · Granted Aug 31, 2021 · Expires Aug 26, 2041

    granted

  8. US 11103513

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Aug 31, 2021 · Expires Aug 26, 2041

    granted

  9. US 11090344

    Adenovirus and immunomodulator combination therapy

    The Board of Regents of the University of Texas System · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted

  10. US 11077241

    Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or bone marrow concentrate (BMC) alone or in combination with hyaluronic acid

    RegenLab USA LLC · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  11. US 11071781

    Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted

  12. US 11071778

    Combination product for use in tumor vaccination

    DCPRIME B.V. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted

  13. US 11065214

    Combination therapies with disulfiram

    Spring Discovery, Inc. · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  14. US 11065285

    Biomarkers and combination therapies using oncolytic virus and immunomodulation

    The Board of Regents of the University of Texas System · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  15. US 11065332

    Combination therapy of immunotoxin and checkpoint inhibitor

    The Government of The United States as Represented by the Secretary of Health and Human Services, National Institutes of Health · Granted Jul 20, 2021 · Expires Jul 15, 2041

    granted

  16. US 11059906

    Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma

    Takeda Pharmaceutical Company Limited · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted

  17. US 11033621

    Combination therapies targeting tumor-associated stroma or tumor cells

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  18. US 11033620

    Combination therapies targeting tumor-associated stroma or tumor cells and microtubules

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  19. US 11033516

    Combination therapies with disulfiram

    Spring Discovery, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  20. US 11034757

    Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  21. US 11033537

    LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

    Biomed Valley Discoveries, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  22. US 2021163596

    IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Jun 3, 2021 · Expires May 29, 2041

    granted

  23. US 11013743

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted May 25, 2021 · Expires May 20, 2041

    granted

  24. US 11007183

    Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.